After spending years encouraging and helping train colleagues to treat floaters, Christopher F. Wood, MD, is confident that technologies available today will allow ophthalmologists to popularize the procedure and expand access to many more patients.
More and more companies are looking for novel ways to educate both eye-care professionals and patients about AMD. Here are some of the newer resource materials available.
About 85% to 90% of the cases of macular degeneration are the “dry” (atrophic) type. To date, there are no approved pharmacologic treatments for the dry form of AMD, but there are several studies under way.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
